Medtronic plc stock (IE00BTN1Y115): shares ease after FY 2026 guidance update and 52-week low

Medtronic shares on the New York Stock Exchange traded slightly lower midweek after the medical technology group detailed its fiscal 2026 results and fiscal 2027 guidance, leaving the stock near a fresh 52-week low despite the strongest annual revenue growth in a decade.

Medtronic shares on the New York Stock Exchange traded moderately lower in midweek trading after the Dublin-based medical technology group followed up its fiscal 2026 earnings release and fiscal 2027 guidance with continued pressure on the stock price, keeping the share close to its latest 52-week low in the United States.

According to a Form 8-K filed with the U.S. Securities and Exchange Commission on 05/27/2026, Medtronic reported fourth-quarter fiscal 2026 revenue of USD 9.807 billion, representing 9.9% year-on-year growth and contributing to its fastest annual revenue expansion in 10 years, while full-year revenue reached USD 34.1 billion with organic growth in the mid-single digits.SEC filing summary as of 05/27/2026

The same 8-K filing shows that Medtronic issued fiscal 2027 guidance pointing to continued revenue expansion but with an earnings profile that some investors viewed as conservative relative to market expectations, contributing to a cautious reaction in U.S. trading sessions in late May and early June.SEC filing summary as of 05/27/2026

On the NYSE, the stock most recently changed hands around the mid-USD 70s, after touching a 52-week low of USD 75.91 in late May, a level that corresponds to a drop of roughly 19% year-to-date as tracked by broader market data.Market data snapshot as of 06/03/2026

In Germany, Medtronic is also tradable via platforms such as Tradegate in euro, offering an additional access point for investors in the DACH region alongside the primary New York Stock Exchange listing.

The stock reaction has come even as newswire reports highlighted that Medtronic beat Wall Street estimates for fourth-quarter fiscal 2026 revenue and adjusted profit on the back of solid demand for its heart devices and other cardiovascular therapies, underscoring good operational momentum into the new fiscal year.MarketScreener/Reuters report as of 05/27/2026

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Medtronic plc
• Sector/industry: Medical technology, medical devices
• Headquarters/country: Dublin, Ireland
• Core markets: United States, Europe, Asia-Pacific and other international markets
• Key revenue drivers: Cardiovascular, medical surgical, neuroscience and diabetes devices and therapies
• Home exchange/listing venue: New York Stock Exchange (MDT)
• Trading currency: USD

Medtronic plc: core business model

Medtronic focuses on developing and commercializing a broad range of implantable devices, instruments and software used by hospitals and physicians to treat chronic cardiovascular, neurological, surgical and diabetes-related conditions worldwide.

Medtronic plc in peer comparison

Viewed against other large medical technology names, Medtronic sits in a global competitive set that includes U.S.-listed peers such as Edwards Lifesciences and Stryker, which are also key suppliers of devices to hospitals and specialist clinics.

Edwards Lifesciences, best known for its transcatheter heart valves, reported first-quarter 2026 revenue growth in the mid-single digits as it continued to benefit from adoption of minimally invasive procedures in the United States and Europe, according to recent earnings filings and newswire coverage.MarketWatch overview as of 04/2026

Stryker, a leading provider of orthopedic implants and surgical equipment, has also highlighted steady procedure volumes and demand for capital equipment in its most recent quarterly update in early 2026, reflecting a constructive backdrop for hospital spending on advanced medical devices.Wall Street Journal coverage as of 04/2026

In that context, Medtronic’s combination of double-digit reported fourth-quarter revenue growth and its fastest annual revenue expansion in a decade helps position the group competitively within the global medtech sector even as the share price remains under pressure.SEC filing summary as of 05/27/2026

Conclusion

Medtronic’s latest 8-K filing for fiscal 2026 underscores robust fourth-quarter and full-year revenue growth, including its strongest annual revenue expansion in a decade, while fiscal 2027 guidance appears more measured and has coincided with the stock trading near a 52-week low in the United States.

Against established peers such as Edwards Lifesciences and Stryker, which are also navigating steady demand for procedures and hospital equipment, Medtronic’s performance metrics highlight a solid position in global medtech, even if the equity market is currently assigning a cautious valuation.

How the share performs from here will depend in part on execution against the new guidance range, the trajectory of hospital procedure volumes and capital spending, and broader sentiment toward U.S.-listed medical technology stocks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.